The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Neurol.
Sec. Neuro-Otology
Volume 15 - 2024 |
doi: 10.3389/fneur.2024.1410389
Association of the protective effect of telmisartan on hearing loss among patients with hypertension
Provisionally accepted- 1 Korea University Anam Hospital, Seoul, Republic of Korea
- 2 Korea University, Seoul, Republic of Korea
- 3 Korea University Ansan Hospital, Ansan-si, Republic of Korea
- 4 Korea University Guro Hospital, Seoul, Republic of Korea
Aim Hearing loss, affecting a significant portion of the global population, is prevented with peroxisome proliferator-activated receptor γ agonism. Understanding potential protective treatments is crucial for public health. We examine the effect of telmisartan, an antihypertensive drug and partial peroxisome proliferator-activated receptor γ agonist, on hearing loss in patients with hypertension.This retrospective cohort analysis used data from the OMOP Common Data Model database, encompassing information from three tertiary institutions in South Korea. The study included a substantial sample size of 860,103 people diagnosed with hypertension. The study included individuals who had been medically diagnosed with hypertension and had been prescribed antihypertensive drugs, including telmisartan. The study design was established to evaluate the comparative effects of telmisartan and other hypertension medications on hearing loss. We used propensity score matching (PSM) to create a balanced cohort, reducing potential biases between the telmisartan and non-telmisartan groups. From the initial 860,103 patients with hypertension, a propensity score matched cohort was derived from 20,010 patients, with 2,193 in the telmisartan group. After PSM, lower incidence of total hearing loss was observed in the telmisartan group compared to the non-telmisartan group during the 3-year follow-up (0.5% vs. 1.5%, log-rank p=0.005). In subgroup analysis, this study showed consistent results that lower incidence of total hearing loss was higher in the telmisartan group than in the non-telmisartan group. Telmisartan was associated with reducing certain types of hearing loss in patients with hypertension. Further research is needed to confirm these findings and understand the mechanisms.
Keywords: Telmisartan, Hearing Loss, Angiotensin II receptor blocker, PPAR γ agonist, Hypertension
Received: 14 Apr 2024; Accepted: 12 Aug 2024.
Copyright: © 2024 Cha, Yum, Kim, Kim, Rah, Park, IM, Song, Chae, Choi and Joo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yunjin Yum, Korea University, Seoul, 136-701, Republic of Korea
Yong Hyun Kim, Korea University Ansan Hospital, Ansan-si, Republic of Korea
Eung Ju Kim, Korea University Guro Hospital, Seoul, Republic of Korea
Yoon Chan Rah, Korea University Ansan Hospital, Ansan-si, Republic of Korea
Euyhyun Park, Korea University Anam Hospital, Seoul, Republic of Korea
Sung-Won Chae, Korea University Guro Hospital, Seoul, Republic of Korea
June Choi, Korea University Ansan Hospital, Ansan-si, Republic of Korea
Hyung Joon Joo, Korea University Anam Hospital, Seoul, Republic of Korea
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.